Literature DB >> 11274365

PTEN controls tumor-induced angiogenesis.

S Wen1, J Stolarov, M P Myers, J D Su, M H Wigler, N K Tonks, D L Durden.   

Abstract

Mutations of the tumor suppressor PTEN, a phosphatase with specificity for 3-phosphorylated inositol phospholipids, accompany progression of brain tumors from benign to the most malignant forms. Tumor progression, particularly in aggressive and malignant tumors, is associated with the induction of angiogenesis, a process termed the angiogenic switch. Therefore, we tested whether PTEN regulates tumor progression by modulating angiogenesis. U87MG glioma cells stably reconstituted with PTEN cDNA were tested for growth in a nude mouse orthotopic brain tumor model. We observed that the reconstitution of wild-type PTEN had no effect on in vitro proliferation but dramatically decreased tumor growth in vivo and prolonged survival in mice implanted intracranially with these tumor cells. PTEN reconstitution diminished phosphorylation of AKT within the PTEN-reconstituted tumor, induced thrombospondin 1 expression, and suppressed angiogenic activity. These effects were not observed in tumors reconstituted with a lipid phosphatase inactive G129E mutant of PTEN, a result that provides evidence that the lipid phosphatase activity of PTEN regulates the angiogenic response in vivo. These data provide evidence that PTEN regulates tumor-induced angiogenesis and the progression of gliomas to a malignant phenotype via the regulation of phosphoinositide-dependent signals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274365      PMCID: PMC31884          DOI: 10.1073/pnas.081063798

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations.

Authors:  C Raffel; L Frederick; J R O'Fallon; P Atherton-Skaff; A Perry; R B Jenkins; C D James
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

2.  Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding.

Authors:  N B Adey; L Huang; P A Ormonde; M L Baumgard; R Pero; D V Byreddy; S V Tavtigian; P L Bartel
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

3.  Cell cycle arrest and astrocytic differentiation resulting from PTEN expression in glioma cells.

Authors:  J Adachi; K Ohbayashi; T Suzuki; T Sasaki
Journal:  J Neurosurg       Date:  1999-11       Impact factor: 5.115

Review 4.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase.

Authors:  T Maehama; J E Dixon
Journal:  Trends Cell Biol       Date:  1999-04       Impact factor: 20.808

5.  Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma.

Authors:  D Giri; M Ittmann
Journal:  Hum Pathol       Date:  1999-04       Impact factor: 3.466

6.  Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Authors:  J O Lee; H Yang; M M Georgescu; A Di Cristofano; T Maehama; Y Shi; J E Dixon; P Pandolfi; N P Pavletich
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

7.  Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.

Authors:  B H Jiang; J Z Zheng; M Aoki; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  Loss of PTEN facilitates HIF-1-mediated gene expression.

Authors:  W Zundel; C Schindler; D Haas-Kogan; A Koong; F Kaper; E Chen; A R Gottschalk; H E Ryan; R S Johnson; A B Jefferson; D Stokoe; A J Giaccia
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

9.  The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.

Authors:  M M Georgescu; K H Kirsch; T Akagi; T Shishido; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

10.  Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.

Authors:  N R Leslie; A Gray; I Pass; E A Orchiston; C P Downes
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

View more
  79 in total

Review 1.  Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets.

Authors:  A Shir; A Levitzki
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

Review 2.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

3.  PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.

Authors:  Z Meng; L-F Jia; Y-H Gan
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

4.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Authors:  Stacey L Thomas; Ridwan Alam; Nancy Lemke; Lonni R Schultz; Jorge A Gutiérrez; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

5.  Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.

Authors:  Balveen Kaur; Sarah M Cork; Eric M Sandberg; Narra S Devi; Zhaobin Zhang; Philip A Klenotic; Maria Febbraio; Hyunsuk Shim; Hui Mao; Carol Tucker-Burden; Roy L Silverstein; Daniel J Brat; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  Magnetic resonance characteristics of adult-onset Lhermitte-Duclos disease: An indicator for active cancer surveillance?

Authors:  Guangquan Wei; Wei Zhang; Qinlong Li; Xiaowei Kang; Haitao Zhao; Xianping Liu; Xing Tang; Yuanming Wu; Juntao Han; Hong Yin
Journal:  Mol Clin Oncol       Date:  2014-02-12

Review 7.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

Review 8.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

9.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

10.  Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.

Authors:  Jiangang Zhou; Xi Feng; Bin Ban; Jingxia Liu; Zhou Wang; Wuhan Xiao
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.